5 Best Healthcare Stocks For the Long Term

4. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

PE Ratio (TTM): 19.46

Number of Hedge Fund Holders: 27

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is working to develop treatments for neurological diseases. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has gained about 41% over the past 12 months and analysts believe it can run further. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is known for wakix (pitolisant), which is used to address excessive daytime sleepiness. This product alone produced $117 million in revenue in the third quarter, up 45% from the previous year. Some other important possible catalysts for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) from its pipeline include treatments for Myotonic Dystrophy, Idiopathic Hypersomnia and pediatric narcolepsy.

As of the end of the third quarter, 27 hedge funds tracked by Insider Monkey reported having stakes in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY). The total value of these stakes was $338 million. In the previous quarter, 20 funds had stakes in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY). This shows that hedge fund sentiment is strong for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY).